Novel SERD boosts PFS of patients with ER-positive, metastatic breast cancer
Author: Shreeya Nanda medwireNews: A phase 3 trial has demonstrated a significant progression-free survival (PFS) benefit with the oral selective estrogen receptor degrader (SERD) elacestrant relative to standard of care (SOC) in pretreated patients with estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer. Presenting the EMERALD study data at the 2021 San Antonio Breast Cancer Symposium, […]
At a glance: First-line immunotherapy for advanced urothelial carcinoma
Author: Shreeya Nanda The treatment landscape of advanced urothelial carcinoma has changed considerably in the past few years, with immunotherapy becoming a key component. In this article, we provide an overview of the published trials of PD-1 pathway and CTLA-4 inhibitors – used as monotherapy, in combination with chemotherapy, or as maintenance – in the […]
ASCO 2021 Lung cancer: Clinical insights into key research
Gilberto Lopes shares his lung cancer highlights from the 2021 ASCO Annual Meeting, including the IMpower010 trial, the MYLUNG study of real-world molecular testing, and updates on the CodeBreaK 100 and CHRYSALIS studies (8:06). 00:00 – Introduction00:30 – MYLUNG study02:44 – CodeBreaK 100 trial03:52 – CHRYSALIS trial04:48 – IMpower010 trial Read transcript Hello. Thank you […]
PEACE-1 points to benefit of adding abiraterone to ADT–docetaxel in de novo mCSPC
Karim Fizazi describes results from the phase 3 PEACE-1 trial suggesting that the combination of abiraterone, androgen deprivation therapy, and docetaxel could be an option for patients with a new diagnosis of metastatic castration-sensitive prostate cancer (5:58).
At a glance: The JAVELIN lung cancer trials
Author: Hannah Kitt The PD-L1 inhibitor avelumab (formerly MSB0010718C) is being evaluated in the JAVELIN clinical trials as a single agent or in combination with an assortment of anticancer agents for the treatment of various malignancies. Here is a quick guide to the nine JAVELIN trials investigating avelumab in patients with non-small-cell lung cancer (NSCLC), […]
COVID-19 vaccination in patients with cancer
We speak to medical oncologist Narjust Duma, from the University of Wisconsin in the USA, about COVID-19 vaccination in people with cancer, discussing issues such as the timing of vaccine administration, the importance of monitoring side effects, and the key unanswered research questions. We speak to medical oncologist Narjust Duma, from the University of Wisconsin […]
Metastatic urothelial cancer: clinical insights into trial data
Shilpa Gupta and Petros Grivas share their thoughts on the key practicing-changing trials in metastatic urothelial cancer, including EV-301, EV-201, TITAN-TCC, and TROPiCS-04, and discuss the emerging role of antibody–drug conjugates in the evolving treatment landscape (16:47).
At a glance: The CheckMate RCC trials
Author: Shreeya Nanda This article provides a top-line overview of the CheckMate clinical trials of the PD-1 inhibitor nivolumab – either given alone or alongside the CTLA-4 inhibitor ipilimumab – in patients with renal cell carcinoma (RCC). There are nine trials at the time of writing, all of which are sponsored by the drug manufacturer […]
At a glance: The KEYNOTE lung cancer trials
Updated July 2019 Author: Shreeya Nanda The PD-1 inhibitor pembrolizumab is being investigated in multiple KEYNOTE trials across different tumor types, either alone or as part of various combinations, leading to a prodigious amount of information. Here we provide a quick guide to the non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) trials sponsored […]
